Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gaviscon Double Action in GERD
NCT01869491Phase 3Completed
- Sponsor
- Reckitt
- Start
- Jun 2013
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Gaviscon Double Action in gastroesophageal reflux disease (GERD), dyspepsia, sponsored by Reckitt. Started Jun 2013; status: completed.
02
Drugs
Gaviscon Double Action
03
Conditions
gastroesophageal reflux disease (GERD)dyspepsia
Beyond the preview
Go deeper on NCT01869491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01869491.